Canadian Melanoma Conference: Research Frontiers

Alberta Cancer Board
Last Modified: January 15, 2006

Conference Dates: Thursday, March 2, 2006 to Monday, March 6, 2006
Conference Location: The Fairmont Banff Springs Hotel, Banff, Alberta

Sponsoring Group: Alberta Cancer Board

Conference Web Page URL: http://www.buksa.com

Topics Covered:

siRNA guided Approach to Melanoma
Treatment Targeted therapy: Sorafenib and ongoing trials
Melanogenesis targeted Nanomedicine
Signal Transduction Inhibitor for Melanoma Immunotherapy
Update and Overview of NCI clinical trials with molecularly targeted agents
p53 Suppression: The Potential of EL625
Managing the patient with moles & the follow up of patients with Metastatic Melanoma
Oncolytic viruses reference to melanoma
Development of melanoma vaccine: possible Phase I/II studies

Conference Objectives: What should the next adjuvant melanoma trial be (the experimental arm, what vaccines, what molecules…)? Can we be rational about selecting investigational molecular therapies / methods, based on what we know about the biology of the disease? Is DTIC still the standard in metastatic disease? Have we made any progress in metastatic disease?

Who Should Attend: Medical Oncologists, Surgeons (General, Oncological, Plastics), Dermatologists, Pathologists, Molecular Biologists, Immunologists

Conference Agenda: TBA

Registration Information: For More Information Canadian Melanoma Conference Secretariat BUKSA Conference Management and Program Development Tel: 780.436.0983 Ext. 229 Fax: 780.437.5984 Toll Free (within North America): 866.436.0983 Ext. 229 Email: melanoma@buksa.com.

Conference Fees: Regular: $250.00 (CDN) - Student: $150.00 (CDN) - One Day: $100.00

Continuing Education: Yes